Weight Loss Interventions to Reduce Cancer Progression in Prostate Cancer Patients Under Active Surveillance
Not Applicable
Active, not recruiting
- Conditions
- Prostate Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Dietary InterventionBehavioral: Fasting
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05764330
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Phase 1
Terminated
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Unresectable Triple-Negative Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: BiopsyProcedure: Computed TomographyBiological: Interferon Alpha-2Procedure: Magnetic Resonance Imaging
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT05756166
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaRefractory Triple-Negative Breast CarcinomaUnresectable Triple-Negative Breast Carcinoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyOther: Questionnaire Administration
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT05741164
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Locally Advanced Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Locally Advanced Esophageal AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Esophageal AdenocarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaClinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyOther: Questionnaire Administration
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05651594
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1
Withdrawn
- Conditions
- Cytomegaloviral InfectionHematopoietic and Lymphoid System Neoplasm
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionBiological: CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT05589844
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Behavioral Parenting Skills As A Novel Target for Improving Pediatric Medication Adherence
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Other: Survey Administration
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 51
- Registration Number
- NCT05587582
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer
Phase 2
Withdrawn
- Conditions
- Unresectable Triple-Negative Breast CarcinomaMetastatic Triple-Negative Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8
- Interventions
- Biological: Alpha-type-1 Polarized Dendritic CellsProcedure: BiopsyProcedure: Computed TomographyProcedure: LeukapheresisOther: Quality-of-Life Assessment
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT05539365
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Phase 2
Not yet recruiting
- Conditions
- Stage III Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Recurrent Colorectal CarcinomaUnresectable Colorectal CarcinomaMetastatic Microsatellite Stable Colorectal Carcinoma
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05518032
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems
Not Applicable
Completed
- Conditions
- Electronic Cigarette Use
- Interventions
- Other: E-cigarette FlavorOther: Tobacco Free Nicotine Pouch
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 163
- Registration Number
- NCT05423340
- Locations
- πΊπΈ
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial
Not Applicable
Suspended
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Other: Quality-of-Life AssessmentOther: Palliative TherapyOther: Questionnaire Administration
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 200
- Registration Number
- NCT05338905
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States